Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138386 | 0.87 | CPB1 (0.48) | AGTR2TSHRALDH1A1ACHECPB1 | |
| SCHEMBL18630854 | 0.83 | KMT2A (0.49) | EPHX2CPB1 | |
| SCHEMBL22614066 | 0.83 | LMNA (0.40) | LMNAAGTR2ACHEEPHX2FFAR4 | |
| SCHEMBL22613920 | 0.83 | LMNA (0.40) | LMNAAGTR2ACHEEPHX2FFAR4 | |
| SCHEMBL22613917 | 0.83 | LMNA (0.40) | LMNAAGTR2ACHEEPHX2FFAR4 | |
| SCHEMBL5924916 | 0.78 | FFAR4 (0.57) | LMNAAGTR2TSHRALDH1A1FFAR4 | |
| SCHEMBL29018749 | 0.78 | FFAR4 (0.57) | LMNAAGTR2TSHRALDH1A1FFAR4 | |
| SCHEMBL29188003 | 0.78 | FFAR4 (0.57) | LMNAAGTR2TSHRALDH1A1FFAR4 | |
| SCHEMBL5447182 | 0.78 | FFAR4 (0.57) | LMNAAGTR2TSHRALDH1A1FFAR4 | |
| SCHEMBL17391191 | 0.78 | FFAR4 (0.57) | LMNAAGTR2TSHRALDH1A1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | GOLDSTEIN SOLO (FR) | 2005-02-10 | — | — | US | disclosed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | CHRNA1, CHRNA4, CHRNB1 | LMNA 3499/4885AGTR2 285/4885TSHR 201/4885 |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | HCAR1, CHRNA1, CNR1 | LMNA 3399/4885AGTR2 244/4885TSHR 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.